Recurrent Olfactory Neuroblastoma Treated With Cetuximab and Sunitinib: A Case Report

DSpace/Manakin Repository

Recurrent Olfactory Neuroblastoma Treated With Cetuximab and Sunitinib: A Case Report

Citable link to this page

 

 
Title: Recurrent Olfactory Neuroblastoma Treated With Cetuximab and Sunitinib: A Case Report
Author: Wang, Lizhi; Ding, Yan; Wei, Lai; Zhao, Dewei; Wang, Ruoyu; Zhang, Yuewei; Gu, Xuesong; Wang, Zhiqiang

Note: Order does not necessarily reflect citation order of authors.

Citation: Wang, Lizhi, Yan Ding, Lai Wei, Dewei Zhao, Ruoyu Wang, Yuewei Zhang, Xuesong Gu, and Zhiqiang Wang. 2016. “Recurrent Olfactory Neuroblastoma Treated With Cetuximab and Sunitinib: A Case Report.” Medicine 95 (18): e3536. doi:10.1097/MD.0000000000003536. http://dx.doi.org/10.1097/MD.0000000000003536.
Full Text & Related Files:
Abstract: Abstract Olfactory neuroblastoma (ONB) is a rare cancer originating in the olfactory epithelium of the nasal vault. The recurrence rate of ONB is high, as the standard treatment of surgery followed by radiotherapy and/or chemotherapy is usually unsuccessful. The use of targeted therapy based on individual genomic variations after cancer relapse has not been reported. Here, we present the case of a 44-year-old man who was diagnosed with recurrent ONB and treated with a regimen developed using whole exome sequencing. Potential targets were first identified and then matched to appropriate drugs. Gene mutations in the genes encoding EGFR, FGFR2, KDR, and RET were discovered in the patient's tumor tissue by whole exome sequencing and the patient was treated with a combination of the targeted drugs cetuximab and sunitinib. Five days after treatment, enhancement magnetic resonance imaging showed a 65% reduction in tumor size, and the Visual analog scale headache scores went down to 2/10 from 10/10. Repeat imaging at 1 month showed a complete response. This study represents the first demonstration of an effective personalized treatment of ONB by targeted drugs, and sheds light on how precision medicine can be used to treat recurrent ONB that fails to respond to routine tumor resection, radiotherapy, and/or chemotherapy.
Published Version: doi:10.1097/MD.0000000000003536
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863775/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:27662037
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters